Ami Organics Ltd
P&L
Quarterly Consolidated
vs Q4 FY25
Acutaas Chemicals Q1 FY26 Results: Revenue from Operations at 2,072mn, up 17.3% YoY
30 Jul 2025 · 30 Jul 2025, 02:26 pm
Summary
Acutaas Chemicals Limited, a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, announced financial results for the quarter ended June 30, 2025. The company reported a 17.3% YoY increase in revenue from operations, with EBITDA margin expanding by 785bps YoY to 24.6%. The company is confident to deliver 25% growth with improved margins in FY26.
Key Highlights
- 1
Q1FY26 Revenue from Operations grew by 17.3% YoY to Rs. 2,072 mn
- 2
Gross margin for the quarter improved to 53.2% up 1,117 bps YoY
- 3
EBITDA for the quarter came at Rs. 509 mn up 72.4% YoY
- 4
EBITDA margin for the quarter was at 24.6% as compared to 16.7% in QIFY25
- 5
PAT for the quarter was Rs. 440 mn up 199.6% as compared to PAT of Rs. 147 mnin QiFY25
- 6
PAT margin for the quarter was at 21.2% up 1,292 bps YoY
- 7
Export for the quarter at 60%; domestic business at 40%
Management Comments
Mr. Naresh Patel
I’m happy to share that we’ve had a strong start to FY26, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. Both our pharma facilities are now PMDA GMP certified, underscoring our commitment to global compliance and quality. I’m happy to announce that we have entered into a joint venture in South Korea which brings us closer to key semiconductor markets and strengthens our portfolio with differentiated, high-value products tailored for this space. With rising customer engagement across CDMO, battery chemicals, and semiconductors, we step into FY26 with strong momentum and confidence to deliver 25% growth with improved margins.
Informational and educational content only. Not investment advice.